| Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies (NCT06652633) | Lakefront Biotherapeutics NV | 2024-09-09 |
| Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects (NCT06043739) | Lakefront Biotherapeutics NV | 2023-09-22 |
| A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus (NCT05856448) | Lakefront Biotherapeutics NV | 2023-06-28 |
| A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis (NCT05695950) | Lakefront Biotherapeutics NV | 2023-02-27 |
| A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission (NCT05479058) | Lakefront Biotherapeutics NV | 2022-07-26 |
| A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma (NCT06561425) | Lakefront Biotherapeutics NV | 2022-03-09 |
| Drug-drug Interaction Study with GLPG3667 and Itraconazole in Healthy Subjects (NCT05272683) | Lakefront Biotherapeutics NV | 2022-02-28 |
| Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects (NCT05030857) | Lakefront Biotherapeutics NV | 2021-09-08 |
| A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects (NCT04976270) | Lakefront Biotherapeutics NV | 2021-07-20 |
| Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects (NCT04971746) | Lakefront Biotherapeutics NV | 2021-07-19 |
| Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970 (NCT04907149) | Lakefront Biotherapeutics NV | 2021-06-07 |
| A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects (NCT04856358) | Lakefront Biotherapeutics NV | 2021-04-27 |
| A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS) (NCT04700280) | Lakefront Biotherapeutics NV | 2021-01-28 |
| Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy Subjects (NCT04736927) | Lakefront Biotherapeutics NV | 2021-01-15 |
| Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205 (NCT04704739) | Lakefront Biotherapeutics NV | 2021-01-13 |
| Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects (NCT04720183) | Lakefront Biotherapeutics NV | 2021-01-11 |
| A Study to Assess Relative Bioavailability of and Effect of Food on a New Oral Tablet Formulation of GLPG3970 (NCT04708184) | Lakefront Biotherapeutics NV | 2021-01-11 |
| A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus Erythematosus (NCT04700267) | Lakefront Biotherapeutics NV | 2020-12-28 |
| A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (NCT04578548) | Lakefront Biotherapeutics NV | 2020-11-10 |
| A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult Subjects (NCT04653467) | Lakefront Biotherapeutics NV | 2020-11-06 |
| A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis (NCT04594928) | Lakefront Biotherapeutics NV | 2020-10-19 |
| A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis (NCT04577794) | Lakefront Biotherapeutics NV | 2020-10-05 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male Subjects (NCT04532567) | Lakefront Biotherapeutics NV | 2020-08-18 |
| A Study in Healthy Volunteers to Compare Different Tablet Formulations of the Test Medicine, GLPG1972, Against the Current Tablet Formulation, and to Assess the Effect Food Has on One of the Test Medicines (NCT04137341) | Lakefront Biotherapeutics NV | 2019-10-09 |
| A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667 (NCT04097938) | Lakefront Biotherapeutics NV | 2019-09-18 |
| A Study in Healthy Male Volunteers to Test How the Test Medicine GLPG1972 is Taken up by the Body When Given by Mouth and Into the Vein as an Injection (NCT04136327) | Lakefront Biotherapeutics NV | 2019-09-13 |
| A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970 (NCT04106297) | Lakefront Biotherapeutics NV | 2019-09-10 |
| A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis (NCT03976648) | Lakefront Biotherapeutics NV | 2019-07-18 |
| Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis (NCT03926195) | Lakefront Biotherapeutics NV | 2019-05-28 |
| A Study to Evaluate the Effects of a Single and Multiple Oral Doses of GLPG3121 in Adult, Healthy, Male Subjects (NCT03899909) | Lakefront Biotherapeutics NV | 2019-03-29 |
| A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis (NCT03864627) | Lakefront Biotherapeutics NV | 2019-03-25 |
| A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatment of Inflammatory Diseases (NCT03800472) | Lakefront Biotherapeutics NV | 2019-01-15 |
| A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis (NCT03798366) | Lakefront Biotherapeutics NV | 2019-01-14 |
| A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care (NCT03711162) | Lakefront Biotherapeutics NV | 2018-11-28 |
| A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Given by Mouth and Into a Vein as an Injection (NCT03787186) | Lakefront Biotherapeutics NV | 2018-11-09 |
| A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) (NCT03725852) | Lakefront Biotherapeutics NV | 2018-09-27 |
| A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis (NCT03595618) | Lakefront Biotherapeutics NV | 2018-08-14 |
| A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis (NCT03689829) | Lakefront Biotherapeutics NV | 2018-08-13 |
| A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis. (NCT03540524) | Lakefront Biotherapeutics NV | 2018-05-31 |
| A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis (NCT03568071) | Lakefront Biotherapeutics NV | 2018-04-26 |
| A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers (NCT03515382) | Lakefront Biotherapeutics NV | 2018-03-16 |
| Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis. (NCT03589313) | Lakefront Biotherapeutics NV | 2018-02-12 |
| GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis (NCT03474042) | Lakefront Biotherapeutics NV | 2017-11-29 |